NC
KERX

Northpointe Capital’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Northpointe Capital’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-426,849
Closed -$5.43M – 254
2015
Q1 		$5.43M Sell
426,849
-87,596
-17% -$1.13M 0.59% 53
2014
Q4 		$7.28M Buy
514,445
+49,650
+11% +$769K 0.87% 30
2014
Q3 		$6.39M Sell
464,795
-427,216
-48% -$6.54M 0.68% 60
2014
Q2 		$13.7M Buy
892,011
+14,136
+2% +$200K 1.32% 7
2014
Q1 		$15M Sell
877,875
-411,836
-32% -$6.21M 1.52% 9
2013
Q4 		$16.7M Buy
1,289,711
+228,285
+22% +$2.73M 1.47% 14
2013
Q3 		$10.7M Sell
1,061,426
-43,840
-4% -$390K 1.26% 21
2013
Q2 		$8.26M Buy
+1,105,266
New +$8.64M 0.95% 32

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

Northpointe Capital's KERX Position: Q2 2015 in Review

Northpointe Capital sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2015, closing a stake of 426,849 shares — an estimated $5.43M sold.

Northpointe Capital first reported a position in KERX in Q2 2013 and held it in 8 quarters. The position peaked at $16.7M in Q4 2013. 153 funds tracked by Wall St. Rank hold KERX as of Q2 2015.

  • Northpointe Capital reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2015 after selling out during the quarter.
  • Northpointe Capital sold 426,849 Keryx Biopharmaceuticals Inc shares in Q2 2015, an estimated $5.43M.
  • Northpointe Capital first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 8 quarters.
  • Northpointe Capital's Keryx Biopharmaceuticals Inc position peaked at $16.7M in Q4 2013.
  • 153 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2015.

Based on Northpointe Capital's 13F filing for Q2 2015, filed 30 Jul 2015.